GGrantIndex
← Search

Research Program: Pathogen Associated Malignancies

$80,941P30FY2022CANIH

Fred Hutchinson Cancer Center, Seattle WA

Investigators

Linked publications, trials & patents

Trial NCT06995898Trial NCT06682039Trial NCT06484595Trial NCT06193070Trial NCT05947500Trial NCT05930496Trial NCT05183828Trial NCT04902144Trial NCT04751383Trial NCT04682301Trial NCT04667481Trial NCT04660331Trial NCT04539366Trial NCT04505553Trial NCT04502524Trial NCT04500548Trial NCT04496219Trial NCT04489719Trial NCT04472338Trial NCT04466475Trial NCT04447313Trial NCT04444232Trial NCT04442581Trial NCT04431479Trial NCT04410900Trial NCT04387227Trial NCT04384692Trial NCT04383743Trial NCT04375631Trial NCT04372927Trial NCT04370301Trial NCT04359784Trial NCT04336943Trial NCT04329065Trial NCT04282187Trial NCT04260776Trial NCT04257578Trial NCT04254133Trial NCT04231877Trial NCT04220229Trial NCT04211766Trial NCT04208724Trial NCT04205409Trial NCT04200482Trial NCT04198922Trial NCT04196010Trial NCT04195945Trial NCT04195633Trial NCT04194918Trial NCT04188912Trial NCT04175431Trial NCT04156828Trial NCT04155840Trial NCT04151940Trial NCT04120246Trial NCT04111497Trial NCT04083183Trial NCT04083170Trial NCT04081779Trial NCT04081298Trial NCT04062955Trial NCT04060849Trial NCT03999515Trial NCT03991884Trial NCT03986502Trial NCT03980769Trial NCT03970096Trial NCT03907527Trial NCT03891784Trial NCT03864419Trial NCT03807063Trial NCT03806192Trial NCT03781778Trial NCT03779867Trial NCT03779854Trial NCT03778021Trial NCT03776864Trial NCT03749460Trial NCT03747484Trial NCT03737955Trial NCT03723863Trial NCT03718338Trial NCT03672981Trial NCT03670966Trial NCT03670069Trial NCT03660930Trial NCT03649841Trial NCT03641287Trial NCT03606486Trial NCT03602898Trial NCT03600038Trial NCT03585231Trial NCT03574012Trial NCT03570476Trial NCT03531918Trial NCT03525106Trial NCT03523195Trial NCT03522584Trial NCT03518242Trial NCT03516812

Abstract

PROJECT SUMMARY: PATHOGEN ASSOCIATED MALIGNANCIES (PAM) The overall focus of this program is to study pathogen-associated malignancies (PAM) to better prevent, diagnose, and treat these cancers. We will place an emphasis on studying host-pathogen interactions to identify novel vulnerabilities caused by the pathogens and will use this information to design prevention or treatment strategies. We will focus on anogenital and oropharyngeal cancers caused by human papillomaviruses (HPV), Merkel cell carcinoma (MCC) caused by Merkel cell polyomavirus (MCPyV), gastric cancers caused by Helicobacter pylori (H. pylori), Kaposi sarcoma and other lymphomas caused by Kaposi sarcoma herpesvirus (KSHV), liver cancers caused by hepatitis B and C viruses (HBV, HCV), and both lymphomas and epithelial cancers caused by Epstein Barr virus (EBV). Additionally, we will study the role that specific bacteria or the microbiome play in promoting cancer and in modifying response to treatment modalities. The specific aims of the program are (1) to study host-pathogen interactions of PAMs to identify mechanisms of cancer induction and exploitable vulnerabilities, (2) to support translational studies of PAMs in preclinical and clinical settings that can inform the design of better prevention or therapeutic strategies, and (3) to implement effective public health measures to eliminate PAMs and adapt the advances in cancer research made in resource-rich countries to address the cancer burdens of low income countries. The PAM Program currently has 37 members with 14 members having primary appointments at Fred Hutch, 22 members at University of Washington, and 1 member at Seattle Children’s. The current research support of PAM members is $26.4M (direct costs), of which $7.6M is peer-reviewed funding, including $2M from the NCI. The PAM program published a total of 377 papers in the last grant period, of which 16% were intra- programmatic, 44% were inter-programmatic, 52% were inter-institutional, and 45% had external co-authors. Program members have utilized all 12 of the Consortium Shared Resources. This P30 grant also assists this program by providing administrative and logistical support for PAM meetings, pilot funding for new research projects, and recruitment resources for new faculty.

View original record on NIH RePORTER →